UNSPSC 51434101: Azamethonium

This classification denotes an antihypertensive agent with the molecular formula C13H33N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 43XK6AW58D, chemically known as ((methylimino)diethylene)bis(ethyldimethylammonium) but generally known as azamethonium, which bears US NIH Compound Identifier 9383. European Medicines Agency schedules Azamethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21910. The term AZAMETHONIUM is an International Non-Proprietary Name.

As of Q4 2014, AZAMETHONIUM remains the US FDA Preferred Term for this commodity. Azamethonium bears US NLM identifiers UMLS ID C2346893 and NCI Concept Code C73610. SMILES: CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC.

UNSPSC 51434101 Azamethonium, a Commodity code, nominally addresses a specific pharmaceutical agent, but state and local procurement activity under this code reflects broader emergency medical and pharmacy benefit procurement. The City of Tampa is soliciting advanced life support medications including epinephrine, labetalol, adenosine, and diltiazem for Tampa Fire Rescue through an IFB posted April 24, 2026, with response due April 8, 2026 (estimated value $40,000.00). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information (RFI) on March 27, 2026, regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking vendor capabilities for direct contracting with self-insured employers and state agencies outside traditional PBM and GPO channels. State and local issuing bodies under this code span municipal fire departments, state pharmacy commissions, and multistate cooperative purchasing alliances, reflecting the fragmented nature of pharmaceutical procurement across emergency medical services and health plan administration.

Geographic activity centers on Texas, Minnesota (serving multiple states including Oregon), and Florida, with opportunities ranging from local emergency medical supply contracts to statewide multistate cooperative arrangements. The Tampa procurement requires medications with nine-month minimum expiration dates and firm pricing including freight to Florida; MMCAP's RFP mandates cGMP and DSCSA compliance, $5 million commercial general liability insurance, and pricing submitted in multiple formats (flat price, net price variants, WAC-minus). The Tampa bid includes a 5 percent SLBE bid discount (not to exceed $10,000) and accessibility conformance to WCAG 2.2 Level AA and Section 508 standards; OSHA Safety Data Sheets are required for all supplied medications. Vendors pursuing MMCAP's multistate contract face 3 percent administrative fees, performance penalties up to $1,500 per violation, and contractual terms extending to June 30, 2028 for incumbents. The Texas RFI remains preliminary market intelligence and does not specify budget, award amounts, or formal evaluation criteria, positioning it as foundational research before formal RFP issuance.